VALIANTLABPharmaceuticals
Valiant Laboratories Ltd — Profit & Loss Statement
₹51.62
-5.74%
Valiant Laboratories Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 0.00 | -0.03 Cr | — |
| Tax Rate For Calcs | 0.30 | 0.30 | 0.24 | 0.34 | — |
| Normalized EBITDA | 0.76 Cr | 1.27 Cr | 39.95 Cr | 44.36 Cr | — |
| Total Unusual Items | 0.00 | 0.00 | 0.00 | -0.10 Cr | — |
| Total Unusual Items Excluding Goodwill | 0.00 | 0.00 | 0.00 | -0.10 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | -2.20 Cr | 0.32 Cr | 29.00 Cr | 27.50 Cr | — |
| Reconciled Depreciation | 2.09 Cr | 1.97 Cr | 1.56 Cr | 2.49 Cr | — |
| Reconciled Cost Of Revenue | 116.60 Cr | 168.25 Cr | 277.32 Cr | 239.20 Cr | — |
| EBITDA | 0.76 Cr | 1.27 Cr | 39.95 Cr | 44.27 Cr | — |
| EBIT | -1.34 Cr | -0.69 Cr | 38.39 Cr | 41.78 Cr | — |
| Net Interest Income | -0.18 Cr | -0.08 Cr | -0.25 Cr | 0.47 Cr | — |
| Interest Expense | 0.18 Cr | 0.08 Cr | 0.25 Cr | 0.07 Cr | — |
| Normalized Income | -2.20 Cr | 0.32 Cr | 29.00 Cr | 27.56 Cr | — |
| Net Income From Continuing And Discontinued Operation | -2.20 Cr | 0.32 Cr | 29.00 Cr | 27.50 Cr | — |
| Total Expenses | 140.15 Cr | 192.43 Cr | 300.38 Cr | 251.52 Cr | — |
| Diluted Average Shares | 4.65 Cr | 4.68 Cr | 4.68 Cr | 4.68 Cr | 4.34 Cr |
| Basic Average Shares | 4.65 Cr | 4.68 Cr | 4.68 Cr | 4.68 Cr | 4.34 Cr |
| Diluted EPS | -0.47 | 0.12 | 6.19 | 5.87 | 7.04 |
| Basic EPS | -0.47 | 0.12 | 6.19 | 5.87 | 7.04 |
| Diluted NI Availto Com Stockholders | -2.20 Cr | 0.32 Cr | 29.00 Cr | 27.50 Cr | — |
| Net Income Common Stockholders | -2.20 Cr | 0.32 Cr | 29.00 Cr | 27.50 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | -2.20 Cr | 0.32 Cr | 29.00 Cr | 27.50 Cr | — |
| Net Income Including Noncontrolling Interests | -2.20 Cr | 0.32 Cr | 29.00 Cr | 27.50 Cr | — |
| Net Income Continuous Operations | -2.20 Cr | 0.32 Cr | 29.00 Cr | 27.50 Cr | — |
| Tax Provision | 0.69 Cr | -1.09 Cr | 9.14 Cr | 14.21 Cr | — |
| Pretax Income | -1.51 Cr | -0.77 Cr | 38.14 Cr | 41.70 Cr | — |
| Other Non Operating Income Expenses | 5.43 Cr | 9.68 Cr | 4.86 Cr | 0.46 Cr | — |
| Special Income Charges | 0.00 | 0.00 | 0.00 | -0.13 Cr | — |
| Net Non Operating Interest Income Expense | -0.18 Cr | -0.08 Cr | -0.25 Cr | 0.47 Cr | — |
| Interest Expense Non Operating | 0.18 Cr | 0.08 Cr | 0.25 Cr | 0.07 Cr | — |
| Operating Income | -6.77 Cr | -10.37 Cr | 33.53 Cr | 40.01 Cr | — |
| Operating Expense | 23.55 Cr | 24.18 Cr | 23.06 Cr | 12.32 Cr | — |
| Other Operating Expenses | 17.07 Cr | 17.90 Cr | 16.89 Cr | 3.50 Cr | — |
| Depreciation And Amortization In Income Statement | 2.09 Cr | 1.97 Cr | 1.56 Cr | 2.49 Cr | — |
| Depreciation Income Statement | 2.09 Cr | 1.97 Cr | 1.56 Cr | 2.49 Cr | — |
| Gross Profit | 16.78 Cr | 13.81 Cr | 56.59 Cr | 52.32 Cr | — |
| Cost Of Revenue | 116.60 Cr | 168.25 Cr | 277.32 Cr | 239.20 Cr | — |
| Total Revenue | 133.38 Cr | 182.06 Cr | 333.91 Cr | 291.52 Cr | — |
| Operating Revenue | 133.38 Cr | 182.06 Cr | 333.91 Cr | 291.52 Cr | — |
| Interest Income | — | — | 0.10 Cr | 0.55 Cr | 0.37 Cr |
| Rent Expense Supplemental | — | — | 0.02 Cr | 0.00 | 0.00 |
| Minority Interests | — | — | 0.00 | — | — |
| Write Off | — | — | 0.22 Cr | 0.17 Cr | 0.00 |
| Interest Income Non Operating | — | — | 0.10 Cr | 0.55 Cr | 0.37 Cr |
| Selling General And Administration | — | — | 2.45 Cr | 1.75 Cr | 1.18 Cr |
| Selling And Marketing Expense | — | — | 1.79 Cr | 1.27 Cr | 0.63 Cr |
| General And Administrative Expense | — | — | 0.65 Cr | 0.48 Cr | 0.56 Cr |
| Rent And Landing Fees | — | — | 0.02 Cr | 0.00 | 0.00 |
| Other Special Charges | — | — | — | -0.04 Cr | — |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Valiant Laboratories Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.